Treatment and outcomes for early non-small-cell lung cancer: a retrospective analysis of a Portuguese hospital database.

This observational study evaluated treatment patterns and survival for patients with stage I-IIIA non-small-cell lung cancer (NSCLC). Adults newly diagnosed with NSCLC in 2012-2016 at IPO-Porto hospital were included. Treatment data were available for patients diagnosed in 2015-2016. 495 patients were included (median age: 67 years). The most common treatments were surgery alone or with another therapy (stage I: 66%) and systemic anticancer therapy plus radiotherapy (stage II: 54%; stage IIIA: 59%). One-year OS (95% CI) for patients with stage I, II and IIIA NSCLC (diagnosed 2012-2016) were 92% (88-96), 71% (62-82) and 69% (63-75), respectively; one-year OS (95% CI) for treated patients with stage I-II or stage IIIA NSCLC (diagnosed 2015-2016) were 89% (81-97) and 86% (75-98) for non-squamous cell and 76% (60-95) and 49% (34-70) for squamous cell NSCLC. Treatment advances are strongly needed for stage I-IIIA NSCLC, especially for patients with squamous cell histology.

Informations de copyright

© 2021 Dr Marta Soares.

Déclaration de conflit d'intérêts

Financial & competing interests disclosure This work was supported by Bristol Myers Squibb. IQVIA received funding from Bristol Myers Squibb to coordinate the data analyses presented in this manuscript. IPO-Porto received funding from IQVIA to perform the analyses planned in the study protocol. All authors were involved in the study design; analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. M Soares, L Antunes, P Redondo, M Borges and MJ Bento are employees of IPO-Porto. M Borges receives personal fees and nonfinancial support from Roche and nonfinancial support from Janssen outside the submitted work. R Hermans, D Patel, F Grimson and R Munro are employees of IQVIA. C Chaib, M Daumont, JR Penrod and JC O'Donnell are employees of Bristol Myers Squibb. C Chaib and JR Penrod report stock ownership in Bristol Myers Squibb. L Lacoin was contracted as a consultant by Bristol Myers Squibb to support the I-O Optimise initiative and is an employee of Epi-Fit. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Professional writing and editorial assistance were provided by B Landry of Parexel, and was funded by Bristol Myers Squibb.